BIOPHARMA
By
Is Novartis Deepening Its Bet on AI-Enabled Molecular Glue Degraders Through an Expanded Collaboration With Monte Rosa?
Novartis AG (SIX: NOVN; NYSE: NVS), a global leader in immunology and targeted therapies, has broadened its partnership…
Will BioNTech and Pfizer’s Counterstrike Against GSK Reshape Europe’s Largest mRNA Patent War?
Key Insights GSK’s Offensive Meets Resistance GSK launched a sweeping litigation campaign in 2024, targeting BioNTech and Pfizer…
Can LB Pharmaceuticals’ $285M IPO Reignite Investor Confidence in Biotech After Months of Silence?
Key Insights IPO Breaks Market Drought LB Pharmaceuticals, a CNS-focused biotech, has defied a months-long IPO drought by…
Is Merck’s £1B Exit Forcing AstraZeneca, Lilly, and Sanofi to Rethink UK’s Life Sciences Future?
Key Insights Merck Triggers Domino Effect with £1B Withdrawal Merck’s decision to abandon its £1-billion London R&D facility…
Has the FDA Approval of Breyanzi Expanded CAR T Cell Therapy Options for Marginal Zone Lymphoma Patients?
Bristol Myers Squibb has received approval from the U.S. Food and Drug Administration for Breyanzi, a CD19-directed CAR…
Does a New Kidney Cancer Trial Expand Long-Term Oncology Optionality for Bristol-Myers Squibb and BioNTech?
December 2025 — Bristol-Myers Squibb and BioNTech have announced progress in their oncology collaboration with the initiation of…
